The chemical composition and energy content of the energetic cosmic radiation

A brief survey is made of our present knowledge of the composition and energy spectra of the primary cosmic radiation. The total energy carried by all forms of cosmic radiation that have appreciable penetrability into matter has been evaluated

Living with helicopter noise : evaluating sound insulation techniques for domestic dwellings using real helicopters

Specific remedial works designed to improve sound installation and reduce the noise level produced by helicopters inside dwellings are described. The theoretical problems and practical solutions to installing high performance acoustic insulation to a traditional property in the UK are presented. A novel application of ISO 140-5 is presented using real helicopters to measure sound insulation in-situ in the presence of multiple flanking transmission paths. Dedicated field trials to evaluate the performance of such acoustic double-glazing and associated modifications systems were performed and the precautions taken to minimise measurement uncertainties over the extended time period of the trials are detailed. The field trials involved the use of military training helicopters following selected flight paths around the property while noise level measurements were made internally and externally, before and after replacement of the existing single glazed windows and attenuated ventilation units were installed. The results show that after replacing the main windows with acoustic insulated glazing units, insulation levels of 40dB or above are achieved in most rooms. The results also illustrate the importance of effectively addressing ventilation when windows are replaced. It is concluded that despite complications due to sound flanking and regulatory ventilation, the use of acoustic double-glazing units and properly attenuated ventilation units can effectively reduce helicopter noise in suitable dwellings

Variations in the propagation of UH-nuclei

Calculations of the propagation of UH-nuclei were improved by extending the number of individual nuclides considered, and by using more recent evaluations of the rigidity dependence of the escape length, the possible source composition, and altered cross sections. The effects of using different expressions for the dependence of abundances on first ionization potentials (FIP) are outlined. The sensitivity of the calculated elemental abundances to the various changes made in the propagation assumptions are discussed

Stopping relativistic Xe, Ho, Au and U nuclei in nuclear emulsions

Nuclei of Xe-54, Ho-67, Au-79 and U-92 accelerated at the Bevalac to energies between 1200 and 900 MeV/n were stopped in nuclear emulsions. The observed residual ranges were compared with those calculated from various models of energy loss and shown to be most consistent with a calculation that includes those higher order correction terms proposed previously to describe the energy loss of highly charged particles, for which the first Born approximation is not valid

The charge and energy spectra of heavy cosmic ray nuclei

A charged particle detector array flown in a high altitude balloon detected and measured some 30,000 cosmic ray nuclei with Z greater than or equal to 12. The charge spectrum at the top of the atmosphere for nuclei with E greater than 650 MeV/n and the energy spectrum for 650 less than or equal to E less than 1800 MeV/n are reported and compared with previously published results. The charge spectrum at the source of cosmic rays is deduced from these data and compared with a recent compilation of galactic abundances

Gamma ray emission from the region of the galactic center

A combination nuclear emulsion-spark chamber gamma ray (E=100 MeV) telescope was used to study the region of sky that includes the Galactic Center. 95% confidence upper limits on the flux from the reported sources G gamma 2 - 3 and Sgr gamma-1 were placed at 4.4 and 8.8 x 10 to the minus 5th power protons/sq cm-sec, and a similar limit on the emission from the Galactic Center as a point source (plus or minus .75 degrees) was placed at 3.3 x 10 to the minus 5th power protons/sq cm-sec. No enhanced emission was observed from the Galactic Plane (plus or minus 6 degrees) and an upper limit of 2 x 10 to the minus 4th power protons/sq cm-sec rad/ was obtained

LDLR-Gene therapy for familial hypercholesterolaemia: Problems, progress, and perspectives

Coronary artery diseases (CAD) inflict a heavy economical and social burden on most populations and contribute significantly to their morbidity and mortality rates. Low-density lipoprotein receptor (LDLR) associated familial hypercholesterolemia (FH) is the most frequent Mendelian disorder and is a major risk factor for the development of CAD. To date there is no cure for FH. The primary goal of clinical management is to control hypercholesterolaemia in order to decrease the risk of atherosclerosis and to prevent CAD. Permanent phenotypic correction with single administration of a gene therapeutic vector is a goal still needing to be achieved. The first ex vivo clinical trial of gene therapy in FH was conducted nearly 18 years ago. Patients who had inherited LDLR gene mutations were subjected to an aggressive surgical intervention involving partial hepatectomy to obtain the patient's own hepatocytes for ex vivo gene transfer with a replication deficient LDLR-retroviral vector. After successful re-infusion of transduced cells through a catheter placed in the inferior mesenteric vein at the time of liver resection, only low-level expression of the transferred LDLR gene was observed in the five patients enrolled in the trial. In contrast, full reversal of hypercholesterolaemia was later demonstrated in in vivo preclinical studies using LDLR-adenovirus mediated gene transfer. However, the high efficiency of cell division independent gene transfer by adenovirus vectors is limited by their short-term persistence due to episomal maintenance and the cytotoxicity of these highly immunogenic viruses. Novel long-term persisting vectors derived from adeno-associated viruses and lentiviruses, are now available and investigations are underway to determine their safety and efficiency in preparation for clinical application for a variety of diseases. Several novel non-viral based therapies have also been developed recently to lower LDL-C serum levels in FH patients. This article reviews the progress made in the 18 years since the first clinical trial for gene therapy of FH, with emphasis on the development, design, performance and limitations of viral based gene transfer vectors used in studies to ameliorate the effects of LDLR deficiency